Literature DB >> 12433264

Survival following a diagnosis of Alzheimer disease.

Ron Brookmeyer1, Maria M Corrada, Frank C Curriero, Claudia Kawas.   

Abstract

CONTEXT: Survival following a diagnosis of Alzheimer disease (AD) is important information for health planners, caregivers, patients, and their families.
OBJECTIVES: To estimate the duration of survival following a diagnosis of AD and to determine the effect of AD on life span. DESIGN, SETTING, AND PARTICIPANTS: Follow-up of participants of the Baltimore Longitudinal Study of Aging who were older than 55 years (January 1, 1985-September 30, 1999). MAIN OUTCOME MEASURES: Survival duration.
RESULTS: The median survival time following a diagnosis of AD depended strongly on the patient's age at diagnosis. The median survival times ranged from 8.3 years for persons diagnosed as having AD at age 65 years to 3.4 years for persons diagnosed as having AD at age 90 years. There were no significant differences between men and women in survival after having a diagnosis of AD. Diagnoses of AD at ages 65 and 90 years were associated with approximately a 67% and 39% reduction in median life span, respectively.
CONCLUSIONS: The effect of a diagnosis of AD on life span depends crucially on the age of the person when AD is diagnosed. Caregivers, patients, and their families could plan on a median life span as long as 7 to 10 years for patients whose conditions are diagnosed when they are in their 60s and early 70s, to only about 3 years or less for patients whose conditions are diagnosed when they are in their 90s.

Entities:  

Mesh:

Year:  2002        PMID: 12433264     DOI: 10.1001/archneur.59.11.1764

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  74 in total

1.  Rapidly progressive Alzheimer's disease mimicking Creutzfeldt-Jakob disease.

Authors:  Susanne Reinwald; Ingo M Westner; Nikolaj Niedermaier
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

2.  Natural history of diseases: Statistical designs and issues.

Authors:  Nicholas P Jewell
Journal:  Clin Pharmacol Ther       Date:  2016-08-18       Impact factor: 6.875

3.  Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease.

Authors:  Lilah M Besser; Dawn P Gill; Sarah E Monsell; Willa Brenowitz; Dana H Meranus; Walter Kukull; Deborah R Gustafson
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

4.  Racial/Ethnic and Nativity Differences in Cognitive Life Expectancies Among Older Adults in the United States.

Authors:  Marc A Garcia; Brian Downer; Chi-Tsun Chiu; Joseph L Saenz; Sunshine Rote; Rebeca Wong
Journal:  Gerontologist       Date:  2019-03-14

Review 5.  A potential role for zinc alterations in the pathogenesis of Alzheimer's disease.

Authors:  Ganna Lyubartseva; Mark A Lovell
Journal:  Biofactors       Date:  2012-03-23       Impact factor: 6.113

6.  Stable size distribution of amyloid plaques over the course of Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew L Mielke; Alona Muzitansky; Teresa Gómez-Isla; John H Growdon; Brian J Bacskai; Rebecca A Betensky; Matthew P Frosch; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2012-08       Impact factor: 3.685

7.  Factors affecting survival of patients with neurodegenerative disease.

Authors:  Kyle Steenland; Jessica MacNeil; Ryan Seals; Allan Levey
Journal:  Neuroepidemiology       Date:  2010-04-08       Impact factor: 3.282

8.  Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.

Authors:  E P Helzner; N Scarmeas; S Cosentino; M X Tang; N Schupf; Y Stern
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

9.  Genetic Determinants of Survival in Patientswith Alzheimer’s Disease.

Authors:  Xingbin Wang; Oscar Lopez; Robert A Sweet; James T Becker; Steven T DeKosky; Mahmud M Barmada; Eleanor Feingold; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.